YITU Attended ICCV 2019 with Self-developed Cloud AI Chip, Showcasing Integrated Software and Hardware Strength
1.11.2019 13:00:00 EET | Business Wire | Press release
The 17th International Conference on Computer Vision (ICCV 2019) was convened in Seoul, South Korea this week. YITU Technology attended the conference with its latest researches. Known as the world’s top-notch computer vision conference, ICCV is held once every two years, of which the papers and topics manifest the highest research level and technical growth trend in the field of computer vision.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191101005240/en/
YITU AI chip QuestCore TM (Photo: Business Wire)
As a globally leading artificial intelligence company, YITU has been always standing at the frontier of AI innovations. From October 29th to November 1st, AI researchers from YITU present their up-to-date research findings and industrial practices at the ICCV 2019, including QuestCoreTM, a cloud AI chip developed by YITU, so as to communicate with and learn from a wider range of research communities.
“The peak of artificial intelligence algorithm performance has shifted from academia to industry,” said Dr. Yan Shuicheng, CTO of YITU, “Academia and industry need in-depth cooperation, to better boost increasing peak performance of the entire AI ecological algorithm.”
As a world-known scholar in computer vision and machine learning, Dr. Yan joined YITU in August this year, the company's strong R&D and engineering strength is one of the important reasons for him to join. Dr. Yan, as an IEEE Fellow, IAPR Fellow and ACM Distinguished Scientist, has published more than 600 papers in top international journals and conferences, with more than 40,000 citations, H-index 98.
YITU released its self-developed cloud AI chip QuestCoreTM in May, 2019. Integrated with its world-class AI algorithm and advanced chip design philosophy, it is so far the most intelligent and cost-effective video analysis chip in the world. This chip indicates a successful practice of YITU to follow the strong coupling trend between AI algorithms and chip design. Relevant achievements are also exhibited on ICCV 2019.
According to data from Tsinghua University, computer vision applications accounted for nearly 35% of the total artificial intelligence applications in 2019, and have become an important support for the development of various industries.
YITU is building the Visual Computing National New Generation Artificial Intelligence Open Innovation Platforman, a national AI infrastructure, to align with the developers of algorithm, chip and product, and provide full chain optimization services covering algorithm, chip and entire tool chain.
“We will help to enhance the overall performance of visual computing smart industry solution,” said Dr. Yan Shuicheng. “Help to integrate development experience and domain knowledge, and promote industrial innovation and cooperation."
About YITU
YITU Technology is one of the few startups in the world that has pioneered many cutting-edge technologies in many critical Artificial Intelligent (AI) fields such as computer vision, speech recognition, natural language processing, intelligent decision-making and AI chips.
YITU Technology is dedicated to advancing breakthrough technologies in AI. Powered by world-class AI algorithms, YITU's self-developed AI chip QuestCore™ can be applied to a variety of scenarios to provide cost-effective and market-competitive solutions. YITU is the only company worldwide to be awarded championship in facial recognition vendor test three times by National Institute of Standards and Technology (NIST), as well as first place in the test hosted by the Intelligence Advanced Research Projects Activity (IARPA). YITU’s self-developed speech recognition technology has been tested to be best-in-class for the Mandarin language. Nature Medicine, a leading academic journal, published on YITU’s latest breakthrough in intelligent pediatric diagnostic technology based on NLP this February, which has been so far the highest-level paper in the field of artificial intelligence research in China.
Leveraging AI technology, YITU is empowering diverse industries. It provides world-leading innovative technologies and products in several sectors including Intelligent City, Smart Finance, Intelligent Healthcare, Smart Retail, AI Chips and AI Pharmaceuticals. YITU is so far the only AI company nationwide able to provide intelligent management technology in mega-cities and complex conditions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191101005240/en/
Contact information
Yitu Tech
Contact name: Alice Deng
Tel:021 - 52559588
Email:media@yitu-inc.com
Website: https://www.yitutech.com/en
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom